MarketCap
Facebook
X
TelegramIntec Pharma Ltd Operating Cycle | NTEC
Annual Operating Cycle Intec Pharma Ltd
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 127 | 120 | 128 | 126 | 135 | 159 | 113 | 110 | 114 | 127 | 132 |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 159 | 110 | 126 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Viridian Therapeutics
VRDN
|
18 | $ 31.22 | 1.17 % | $ 3.18 B |  USA |
 |
Translate Bio, Inc.
TBIO
|
53.1 | - | - | $ 2.81 B | USA |
 |
Trillium Therapeutics Inc.
TRIL
|
295 | - | - | $ 1.94 B |  Canada |
 |
Urovant Sciences Ltd.
UROV
|
65.2 | - | - | $ 532 M |  Britain |
 |
Acceleron Pharma Inc.
XLRN
|
410 | - | - | $ 10.9 B | USA |
 |
Zealand Pharma A/S
ZEAL
|
75.3 | - | 0.52 % | $ 821 M |  Danmark |
 |
Zogenix, Inc.
ZGNX
|
5.04 | - | -4.97 % | $ 664 M | USA |
 |
Yunhong International
ZGYH
|
5.04 | - | 0.10 % | $ 92.2 M |  China |
 |
ZIOPHARM Oncology, Inc.
ZIOP
|
63.5 | - | -7.58 % | $ 264 M | USA |
 |
Vanda Pharmaceuticals
VNDA
|
136 | $ 4.17 | 2.08 % | $ 246 M | USA |
 |
Verrica Pharmaceuticals
VRCA
|
27.2 | $ 3.88 | 10.23 % | $ 41.3 M | USA |
 |
Zymeworks
ZYME
|
211 | $ 29.06 | -7.64 % | $ 1.5 B | Canada |
 |
ADMA Biologics
ADMA
|
391 | $ 13.19 | 4.1 % | $ 3.14 B | USA |
 |
Fate Therapeutics
FATE
|
122 | $ 1.6 | -9.6 % | $ 190 M | USA |
 |
Halozyme Therapeutics
HALO
|
347 | $ 101.68 | -1.26 % | $ 12.2 B | USA |
 |
Hutchison China MediTech Limited
HCM
|
144 | $ 15.09 | -1.92 % | $ 13 B | China |
 |
Aptorum Group Limited
APM
|
106 | - | - | $ 5.72 M | China |
 |
iBio
IBIO
|
3.46 K | $ 0.82 | 5.55 % | $ 85.3 M | USA |
 |
Karyopharm Therapeutics
KPTI
|
71.2 | $ 0.02 | -56.5 % | $ 219 | USA |
 |
FSD Pharma
HUGE
|
3.11 K | - | 5743.5 % | $ 69.7 M | Canada |
 |
Catalyst Pharmaceuticals
CPRX
|
178 | - | - | $ 3.85 B | USA |
 |
UroGen Pharma Ltd.
URGN
|
465 | $ 26.14 | 3.24 % | $ 1.26 B |  Israel |
 |
Catalyst Biosciences
CBIO
|
293 | $ 14.79 | 6.25 % | $ 1.32 B | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
ADiTx Therapeutics
ADTX
|
8.01 K | - | - | $ 374 | USA |
 |
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
115 | - | - | $ 5.18 B | USA |
 |
AstraZeneca PLC
AZN
|
206 | - | - | $ 96.9 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
419 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
EyePoint Pharmaceuticals
EYPT
|
7.32 | $ 0.36 | -10.07 % | $ 26.4 K | USA |
 |
Cara Therapeutics
CARA
|
81.1 | - | -3.03 % | $ 260 M | USA |
 |
ChromaDex Corporation
CDXC
|
142 | - | -0.88 % | $ 598 M | USA |